Platform for novel RNA-modulating drug candidates for rare, nonsense mutation-driven diseases including Cystic Fibrosis
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases.
Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate in the early stages of clinical development focusing on Alport Syndrome and cystic fibrosis. In addition, Eloxx’s innovative TURBO-ZM™ chemistry technology platform provides a pipeline of novel Ribosome Modulating Agents (RMAs) as orally available therapeutics to target select rare diseases including inherited diseases and cancers.
CEO Sumit Aggarwal
Advent Contact Alan Walts
Zikani Therapeutics Completes Series A-1 Funding
Publicly Listed
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Press Release. Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the…
Read More
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Press Release. May 2, 2023ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and FamilialAdenomatous Polyposis (FAP)ZKN-013 is Eloxx’s first drug…
Read More
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations
Press Release. September 9, 2021 WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has…
Read More
